---
title: "Novartis agrees to acquire Anthos for up to $3.1 bln"
date: "2025-02-11 14:32:02"
summary: "Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential additional payment of..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential additional payment of up to $2.15 billion, the company said.

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_TUA9PYNFX:0-novartis-agrees-to-acquire-anthos-for-up-to-3-1-bln/)
